{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-24-000006","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.684543+00:00","generated_at":"2026-06-06T22:03:25.568337+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tarsus CMO Jose Trevejo departs; clinical dev reorganizes under COO","bullets":["Dr. Trevejo steps down as CMO effective Jan 18, 2024; employment ends Feb 17, 2024.","Clinical development and medical affairs reorganized under COO Dr. Sesha Neervannan.","Transition approved Jan 11, 2024; company expresses gratitude for Dr. Trevejo's service."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-24-000006","json":"https://secwatch.observer/filing/0001819790-24-000006.json","markdown":"https://secwatch.observer/filing/0001819790-24-000006.md","text":"https://secwatch.observer/filing/0001819790-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000006/0001819790-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000006/tars-20240111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:03:25.568337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9955a9ae7","claim":"Jose Trevejo departed as Chief Medical Officer at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"On January 18, 2024, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Jose Trevejo, M.D., Ph.D. would be leaving his role as the Company’s Chief Medical Officer (the “Transition”), effective as of January 18, 2024 (the “Transition Date”), and leaving his employment with the Company on February 17, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000006/0001819790-24-000006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}